Chinese Medicine Improves Outcomes In Stemi Patients Stemi patients taking the traditional chinese medicine tongxinluo, containing extracts of multiple plants and insects, had fewer mis, strokes, and other events in the randomized cts ami trial. Conclusions and relevance in patients with stemi, the chinese patent medicine tongxinluo, as an adjunctive therapy in addition to stemi guideline directed treatments, significantly improved both 30 day and 1 year clinical outcomes. further research is needed to determine the mechanism of action of tongxinluo in stemi.
Management And Outcomes Of Patients With Stemi During The Covid 19 Over the past 40 years, outcomes for patients experiencing acute st segment elevation myocardial infarction (stemi) have improved dramatically, fueled by therapeutic interventions proven effective and safe by rigorous clinical trials. 1 those often landmark clinical trials arose from the transformational concept that treatment should be guided. Conclusions and relevance: in patients with stemi, the chinese patent medicine tongxinluo, as an adjunctive therapy in addition to stemi guideline directed treatments, significantly improved both 30 day and 1 year clinical outcomes. further research is needed to determine the mechanism of action of tongxinluo in stemi. A. tongxinluo (txl), a traditional chinese medicine approved to treat angina and stroke in china, significantly improved both the 30 day and one year clinical outcomes of chinese patients with stemi, according to findings from the cts ami trial presented nov. 6 during aha 2022 in chicago. the proof of concept trial randomized 3,777 patients. Tongxinluo, a traditional chinese medicine compound, has shown promise in improving outcomes for patients with st segment elevation myocardial infarction (stemi). this randomized, double blind, placebo controlled trial investigated the efficacy of tongxinluo in reducing major adverse cardiac and cerebrovascular events (macces) in stemi patients.
To Medicalstaff Division Of Coronary Diseases Cardiovascular A. tongxinluo (txl), a traditional chinese medicine approved to treat angina and stroke in china, significantly improved both the 30 day and one year clinical outcomes of chinese patients with stemi, according to findings from the cts ami trial presented nov. 6 during aha 2022 in chicago. the proof of concept trial randomized 3,777 patients. Tongxinluo, a traditional chinese medicine compound, has shown promise in improving outcomes for patients with st segment elevation myocardial infarction (stemi). this randomized, double blind, placebo controlled trial investigated the efficacy of tongxinluo in reducing major adverse cardiac and cerebrovascular events (macces) in stemi patients. In patients with st segment elevation myocardial infarction (stemi), the traditional chinese medicine tongxinluo, as an adjunctive therapy to guideline directed treatment, is associated with. Tongxinluo capsules improve health after heart attack, study shows. certain ingredients that are a part of traditional chinese medicine can have anti inflammatory effects on the heart. michela.
Comments are closed.